InteKrin Therapeutics
Founded Year
2005Stage
Series C | DeadTotal Raised
$41.25MLast Raised
$18.25MAbout InteKrin Therapeutics
InteKrin Therapeutics, Inc. is a privately-held clinical stage biopharmaceutical company based in Los Altos, California developing therapeutics for diabetes, obesity and metabolic disorders. The company was founded in 2005 by Denny Lanfear, a former Vice President and Officer of Amgen, and clinical endocrinologist Christos Mantzoros, M.D., DSc, FACP, FACE, Associate Professor of Medicine at Harvard Medical School. InteKrin's Scientific Advisory Board includes veterans from several successful biopharma organizations, internationally recognized experts in nuclear receptors and metabolism as well as top scientists formerly with the Food and Drug Administration. Its lead product, INT131, is a novel SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator) which is in Phase II clinical trials for diabetes. The company focuses on high value therapeutics in addressing unmet medical needs. To learn more about InteKrin, visit www.intekrin.com
Loading...
Loading...
InteKrin Therapeutics Patents
InteKrin Therapeutics has filed 7 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/7/2016 | 2/11/2020 | Diseases of liver, Diabetes, Hepatology, Syndromes, Rare diseases | Grant |
Application Date | 3/7/2016 |
|---|---|
Grant Date | 2/11/2020 |
Title | |
Related Topics | Diseases of liver, Diabetes, Hepatology, Syndromes, Rare diseases |
Status | Grant |
InteKrin Therapeutics Frequently Asked Questions (FAQ)
When was InteKrin Therapeutics founded?
InteKrin Therapeutics was founded in 2005.
Where is InteKrin Therapeutics's headquarters?
InteKrin Therapeutics's headquarters is located at 4300 El Camino Real, Los Altos.
What is InteKrin Therapeutics's latest funding round?
InteKrin Therapeutics's latest funding round is Series C.
How much did InteKrin Therapeutics raise?
InteKrin Therapeutics raised a total of $41.25M.
Who are the investors of InteKrin Therapeutics?
Investors of InteKrin Therapeutics include Asset Management Ventures, Vivo Capital, Sofinnova Ventures, OrbiMed Advisors, Sears Capital Management and 6 more.
Who are InteKrin Therapeutics's competitors?
Competitors of InteKrin Therapeutics include Intercept Pharmaceuticals, Immunomic Therapeutics, Ambrx, Bicycle Therapeutics, Intarcia Therapeutics and 7 more.
Loading...
Compare InteKrin Therapeutics to Competitors
Intarcia Therapeutics operates as a biopharmaceutical company. The company develops and commercializes therapies to transform the prevention and management of chronic diseases. The company was founded in 1995 and is based in Boston, Massachusetts.
Harkness Pharmaceuticals is focused on developing anti-obesity therapeutics. Per the company, currently more than 20% of the U.S. population are considered clinically obese yet there remain few therapeutic option available. Harkness is performing exploratory human clinical trials in collaboration with the Pennington Institute in Louisiana.
Traversa Therapeutics is a company that operates in the healthcare sector, with a focus on developing therapeutic treatments. The company's main offerings include the development and provision of various therapeutic treatments designed to address different health conditions. It was founded in 2006 and is based in La Jolla, California.
Phytomedics is a biopharmaceutical company based in New Jersey with a broad portfolio of novel compounds for chronic diseases. The lead compound is in clinical development and has shown extraordinary results in clinical trials for the treatment of auto immune disorders like rheumatoid arthritis. The company's platform technology is the basis of their large portfolio of novel therapeutic compounds.
CoImmune is a company that focuses on the development and manufacture of cell-based therapeutics, operating within the healthcare and biotechnology sectors. The company's main offerings include treatments for unmet medical needs such as cancer, autoimmune, and inflammatory diseases. It was founded in 1997 and is based in Durham, North Carolina. CoImmune operates as a subsidiary of Genexine and SCM Lifescience.
Kardia Therapeutics, Inc. is a research-stage biotechnology company focused on the development of cardiac regenerative therapies in the areas myocardial infarction and heart failure. Kardia Therapeutics' portfolio of technologies aims to utilize three related approaches: 1) Adult Cardiac Progenitor Cells, 2) Stem Cell Optimization Technologies, and 3) Homing/Growth Factor Therapies. Because the heart has a limited capacity for self-regeneration, Kardia's technologies have the potential to offer improved patient outcomes compared to existing treatments.
Loading...